All In Biotech

Drug Trial Radar · NCT06627088

A Study of LY4100511 (DC-853) Mass Balance and Absolute Bioavailability of LY4100511 in Healthy Male Participants

A Phase 1, Open-label, Two-part Study of the Absorption, Metabolism, Excretion, and Bioavailability of LY4100511 (DC-853) Following Administration of [14C]-LY4100511 in Healthy Male Participants

Last checked: Nov 19, 2026Latest source record: Jan 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Aug 23, 2024

Primary completion

Dec 31, 2024

Study completion Dec 31, 2024

Sponsor

Sponsor type
Industry
First posted
Oct 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study has two parts, Part A and Part B. The purpose of Part A is to determine the absorption, metabolism, and excretion (AME) of \[14C\]-LY4100511 and to characterize and determine the metabolites present in plasma, urine, and feces in healthy male participants after a single oral dose of LY4100511. The purpose of Part B is to determine the absolute bioavailability of LY4100511 in humans, to further analyze the rate and routes of excretion, including the mass balance, and to further investigate the pharmacokinetics (PK) of \[14C\]-LY4100511, LY4100511, and TRA.

Conditions

  • Healthy

Interventions

  • LY4100511 (DC-853)Drug

    Administered oral dose

  • [14C]-LY4100511 (DC-853) Administered oral doseDrug

    Administered oral dose

  • LY4100511 (DC-853)Drug

    Administered oral dose

  • [14C]-LY4100511 (DC-853)Drug

    Administered IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Total Radioactivity Recovery and Excretion (TRA)Time frame: Up until Day 15
  2. Part A: Pharmacokinetic (PK): Area Under the Concentration from Time 0 to Infinity (AUC0-∞) for [14C] LY4100511Time frame: Up until Day 15
  3. Part A: Pharmacokinetic (PK): Area Under the Concentration from Time 0 to Infinity (AUC0-∞) for LY4100511Time frame: Up until Day 15
  4. Part A: Pharmacokinetic (PK): Area Under the Concentration from Time 0 to Infinity (AUC0-∞) for TRATime frame: Up until Day 15
  5. Part A: PK Area Under Concentration from 0 to Last Measurable Concentration (AUC0-tlast) for [14C] LY4100511Time frame: Up until Day 15
  6. Part A: PK Area Under Concentration from 0 to Last Measurable Concentration (AUC0-tlast) for LY4100511Time frame: Up until Day 15
  7. Part A: PK Area Under Concentration from 0 to Last Measurable Concentration (AUC0-tlast) for TRATime frame: Up until Day 15
  8. Part A: PK Maximum Observed Plasma Concentration (Cmax) for [14C] LY4100511Time frame: Up until Day 15
  9. Part A: PK Maximum Observed Plasma Concentration (Cmax) for LY4100511Time frame: Up until Day 15
  10. Part A: PK Maximum Observed Plasma Concentration (Cmax) for TRATime frame: Up until Day 15
  11. Part A: PK Time to Maximum Observed Plasma Concentration (tmax) for [14C] LY4100511Time frame: Up until Day 15
  12. Part A: PK Time to Maximum Observed Plasma Concentration (tmax) for LY4100511Time frame: Up until Day 15
  13. Part A: PK Time to Maximum Observed Plasma Concentration (tmax) for TRATime frame: Up until Day 15
  14. Part A: PK Terminal Elimination Half Life (t1/2) for [14C] LY4100511Time frame: Up until Day 15
  15. Part A: PK Terminal Elimination Half Life (t1/2) for LY4100511Time frame: Up until Day 15
  16. Part A: PK Terminal Elimination Half Life (t1/2) for TRATime frame: Up until Day 15
  17. Part A: Urinary Recovery and Excretion of TRA (Aet1-t2)Time frame: Up until Day 15
  18. Part A: Urinary Recovery and Excretion of [14C] LY4100511 (Aet1-t2)Time frame: Up until Day 15
  19. Part A: Renal clearance of [14C] LY4100511 (CLR)Time frame: Up until Day 15
  20. Part B: Pharmacokinetic (PK): absolute bioavailability (Fabs) of LY4100511Time frame: Up until Day 6
  21. Part B: Recovery of TRA in urine and fecesTime frame: Up until Day 6
  22. Part B: Recovery of [14C]-LY4100511 in feces (Aet1-t2) following IV dosingTime frame: Up until Day 6
  23. Part B: Recovery of [14C]-LY4100511 in urine (Aet1-t2) following IV dosingTime frame: Up until Day 6
  24. Part B: PK Area Under Concentration from 0 to Last Measurable Concentration (AUC0-tlast) of LY4100511 following IV dosingTime frame: Up until Day 6
  25. Part B: PK Maximum Observed Plasma Concentration (Cmax) of LY4100511following IV dosingTime frame: Up until Day 6
  26. Part B: PK Time to Maximum Observed Plasma Concentration (tmax) of LY4100511following IV dosingTime frame: Up until Day 6
  27. Part B: PK Terminal Elimination Half Life (t1/2) following IV dosingTime frame: Up until Day 6
  28. Part B: PK Clearance (CL) following IV dosingTime frame: Up until Day 6
  29. Part B: PK renal clearance (CLr) following IV dosing [Time Frame: Up until Day 6]Time frame: Up until Day 6

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fortrea Clinical Research Unit

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.